GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clarity Pharmaceuticals Ltd (OTCPK:CLRPF) » Definitions » Other Gross PPE

CLRPF (Clarity Pharmaceuticals) Other Gross PPE : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Clarity Pharmaceuticals Other Gross PPE?

Clarity Pharmaceuticals's Other Gross PPE for the quarter that ended in Dec. 2023 was $0.00 Mil.

Clarity Pharmaceuticals Other Gross PPE Historical Data

The historical data trend for Clarity Pharmaceuticals's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarity Pharmaceuticals Other Gross PPE Chart

Clarity Pharmaceuticals Annual Data
Trend Jun22 Jun23 Jun24
Other Gross PPE
- - -

Clarity Pharmaceuticals Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Other Gross PPE Get a 7-Day Free Trial - - - - -

Clarity Pharmaceuticals Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Clarity Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clarity Pharmaceuticals Ltd (OTCPK:CLRPF) » Definitions » Other Gross PPE
Comparable Companies
ASX:IMU ASX:MSB ASX:OPT ASX:PYC ASX:BOT ASX:IMM ASX:RAC ASX:PAR ASX:PIQ ASX:RCE OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
CU6:Australia
Address
4 Cornwallis Street, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015
Website
https://www.claritypharmaceuticals.com
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology. It operates as a single segment, which is Development of Radiopharmaceuticals. Geographically, it operates in Australia and the United States.